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Accepted 23 October 2013Rhabdomyosarcomas (RMSs) are extremely malignant tumors
originating from myogenic progenitor cells and show variable
stages of skeletal muscle differentiation [1]. They are the most
common soft tissue sarcomas in children and young adults, rep-
resenting 3e6% of all malignancies in this age group [2,3]. The head
and neck is the most common site of RMSs, followed by the geni-
tourinary tract [4]. Twenty percent of primary lesions are localized
in the genitourinary tract, with slightly more than half being the
embryonal RMS type [5].
According to the Intergroup RMS Study Group, there are four
histologic subtypes of RMSs: botryoid and spindle cell, embryonal,
alveolar, and undifferentiated types. The majority of RMSs arising
from the female genital tract are botryoid type, which is a variant of
embryonal rhabdomyosarcoma (ERMS). It arises within the wall of
the bladder or vagina almost exclusively in infants, whereas it can
also arise elsewhere in older children [6]. The sarcoma botryoides
of the cervix uteri very rarely occurs in fertile age; it only accounts
for 0.2% of all malignant tumors of the uterus. At this localization,
the tumor arises from the cervical mucosal epithelium or the
middle tunica, and usually appears as a cervical polyp protruding
out the external oriﬁce. The tumor has a fast growth pattern, mainly
spreading to the lungs and liver by blood circulation [7].
The etiology and speciﬁc risk factors are not known [6]. Diag-
nosis is very challenging because these tumors frequently pose* Corresponding author. Department of Obstetrics and Gynecology, Acıbadem
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techniques such as immunohistochemical staining are often
required to establish a deﬁnite diagnosis. Evaluation of the diag-
nostic material by a pathologist with special expertise in this area is
of utmost importance.
We report a case of ERMS of the uterine cervix in a pregnant
woman. To the best of our knowledge, this is the ﬁrst reported case
of ERMS arising from the uterine cervix in a pregnant woman ac-
cording to the literature search we carried out on PUBMED for the
period of 1971e2013.
A 30-year-old, pregnant woman presented to the afﬁliated
outside clinic with spotting during her 6th gestational week. Her
gynecologist diagnosed a cervical polyp and resected it. According
to the patient's declaration, the pathology result indicated that it
was a benign cervical growth. At the 30th gestational week she
complained of bleeding and a mass protruding from her vagina. On
examination at the same clinic, a 7 cm  5 cm hyperemic mass
originating from the cervical canal was detected. She underwent
polypectomy, and the subsequent pathology report came up as
botryoid type ERMS (Figs. 1e3).
She was referred to our clinic with this result. The results of her
gynecologic and sonographic examinations were unremarkable,
and the metastatic workup was negative. Considering the patient's
age, pregnancy status, and fertility concerns, counseling was given
both to the patient and her family about treatment options and
potential risks. The scarcity of this tumor, lack of a deﬁnitive
treatment plan in adults and particularly in pregnancy, the need for
long-term follow-up, and unforeseeable hazards were all
explained. After conﬁrmation of fetal lung maturation at the 35th
gestational week, pregnancy was terminated by cesarean section.
On postoperative Day 27, she underwent radical hysterectomy,
pelvicepara-aortic systematic lymphadenectomy, and ovarian
transposition. The ﬁnal pathology result was stage 1A embryonal
RMS without lymph node metastasis. In the absence of a deﬁnite
protocol for adults, postoperative adjuvant chemotherapyby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Botyroid embryonal rhabdomyosarcoma. Small, round, and eosinophilic rhab-
domyoblasts (hematoxylin and eosin,  200).
Fig. 3. Botyroid embryonal rhabdomyosarcoma. Desmin immunopositivity in rhab-
domyoblastic cells (immunohistochemistry,  200).
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diatric protocol. Vincristine 1.5 mg/m2 (maximum 2 mg) was given
once a week, with a break for 3 weeks in every 9 weeks, and acti-
nomycine D 0.045 mg/kg (maximum 2.5 mg) was given every 3
weeks, with both drugs being administered for 45 weeks. At the 5th
week of initiation of vincristine treatment, neuropathy occurred,
and the total dosage of vincristine was reduced to 1.6 mg, and to
1.4 mg afterward at the 10th week. At 45 months of follow-up, the
patient showed no evidence of clinical and radiological disease.
Nearly 90% of all cases of RMSs are seen in individuals aged <25
years, and within this age group, 60e70% are <10 years [8,9]. This
tumor is rarely seen in women during fertile period. In a literature
search conducted on PubMed with the keywords RMS and preg-
nancy, we found 13 cases of RMS associated with pregnancy, eight
being in the head and neck, two in the vagina, one in the perineal
region, one in the upper extremity, and one in the kidney. ERMS,
which is a common subtype of RMS in the cervix, is an extremely
rare tumor; as a consequence, related published papers are scarce.
Sarcoma botryoides is a variant of embryonal RMS, and it tends to
occur in the uterine cervix in women of reproductive age. Patients
with cervical sarcoma botryoides usually present with vaginal
bleeding or a feeling of a mass in the vaginal introitus. The ﬁrst
presenting symptom seen in our case was abnormal bleeding at theFig. 2. Botyroid embryonal rhabdomyosarcoma. Small, round, and bizarre rhabdo-
myoblasts (hematoxylin and eosin,  200).6th week of gestation. Another common presenting symptom is a
mass protruding from the vagina, and our patient visited her doctor
with this complaint at the 30th week of her pregnancy. During the
second visit, polypectomy was performed again, and this time the
pathology result came up as ERMS. Although the pathologic result
of the cervical biopsy taken from the polypoid cervical lesion was
consistent with a benign cervical polyp at the 6th week gestational
age, the histopathologic evaluation of the second biopsy specimen
was reported as ERMS with the aid of immunohistochemical
staining at the 30th week of gestation. The ﬁrst pathology report of
our casewas unavailable. According to the patient, shewas told that
she had a benign cervical polyp. It is most probable that the sar-
coma was present at that time, but could not be detected by stan-
dard pathological methods. In most institutions in Turkey,
immunohistochemical staining is not routinely performed and
used only in selected cases.
The microscopic ﬁndings of ERMS consist of rhabdomyoblasts of
varying differentiation dispersed within a loose, myxoid stroma. A
distinct cambium layer beneath the epithelium is a characteristic
feature [10e12]. The immunohistochemical markers that usually
label RMSs are desmin, muscle actin, and myoglobin, with a posi-
tivity rate of 75e100%, 78e97%, and 28e67%, respectively [10]. In
our case, the tumor cells were found positive for desmin, myogenin,
and CD31, but negative for myoglobin. In fact, Daya et al [11] found
that the cases they examined were positive for myoglobin and
desmin if the patients were younger than 30 years, whereas the
tumors of patients older than 40 years rarely showed this charac-
teristic. The positivity of desmin, actin, andmyoglobin also depends
on the tumor's differentiation, having low a sensitivity and speci-
ﬁcity in the absence of a good differentiation. By contrast, myogenin
is considered the most sensible and speciﬁc marker (70e100% of
cases) [13], and we found it positive in our case.
The incidence of RMSs in pregnancy is not clearly known; there
are only anecdotal reports and a few small series published in the
literature [7,14e17]. The diagnosis of cancer during pregnancy often
presents a management dilemma in the aspect of both the mother
and the fetus. Termination of gestation, early delivery of the fetus,
delay of maternal therapy, and initiation of treatment during
pregnancy are the main issues that the clinician should deal with.
There is no consensus regarding the management of malignancies
during pregnancy. When a gynecologic malignancy is diagnosed at
this special period, numerous parameters should be considered in
treatment planning, including gestational age, size and stage of the
tumor, and the patient's desire to preserve the pregnancy, as well as
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removed and fetal lung maturation is awaited, whereas in other
cases, chemotherapy is given during this waiting period [18,19]. The
chemotherapeutics administered in the ﬁrst trimester carry the risk
of fetal malformation, and those used in the second and third tri-
mesters may cause intrauterine growth retardation, prematurity,
low birth weight, and fetal bone marrow suppression [20,21].
When treatment is administered at the third trimester, planning
the delivery 2e3 weeks after the last chemotherapy would impede
both maternal and fetal bone marrow suppression [20]. We also
follow these general rules in our clinic, with the approval of the
family and trying as much as possible to stay within the context of
logical reasoning.
Our patient was in her 30th week of gestation at the time of
diagnosis. However, she had, in fact, ERMS in her uterine cervix
since the 6th gestational week. Therefore, we decided to postpone
the therapy with the patient's desire to preserve the pregnancy
until fetal lung maturation occurred.
Complete excision of the tumor and lymphadenectomy, fol-
lowed by chemotherapy, seems to offer the best prognosis [22e24].
After the cesarean section at the 35th week of gestation, we opted to
use standard treatment for cervical cancer (radical hysterectomy)
and adjuvant chemotherapy according to the pediatric protocol for
RMS, which was started after the surgery.
In a review of the literature, Bansal et al [25] found that among
those who underwent lymphadenectomy, 18.8% of patients with
cervical RMS had nodal disease. Therefore, lymphadenectomy ap-
pears to be critical for this malignancy, in order to detect occult
metastatic disease and also for its potential to provide patients with
a therapeutic beneﬁt.
In conclusion, even though ERMS is a very rare tumor, it should
be included in the differential diagnosis of cervical masses; more-
over, progressively enlarging and bleeding lesions should be bio-
psied even during pregnancy.
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